The New Jersey plant can cater to future expansion plans and establishes Enzene Inc. as a premier global CDMO partner for US biotech firms.
Widely recognised as a pioneer in continuous manufacturing, Pune-based, Contract Development & Manufacturing Organisation (CDMO), Enzene Biosciences has now announced the launch of its first manufacturing site in the United States, located in Hopewell (near Princeton, New Jersey).
The site is expected to be ready in June 2024, and customers have already started to reserve capacities for continuous manufacturing and/or fed batch.
Designed to integrate the company’s patented EnzeneX continuous manufacturing technology platform, the plant is situated within the Princeton West Innovation Campus, at the heart of the US Northeast Corridor, within easy reach of several global biotech and pharmaceutical firms.
This location is ideal for helping Enzene Biosciences serve emerging innovative, US-based biotech firms looking to benefit from the in-depth expertise in continuous manufacturing.
Commenting on the rationale behind setting up its first manufacturing base in the US, Dr Himanshu Gadgil, CEO, Enzene Biosciences, added: “While the USA is home to most of the novel molecules that are the principle ingredients in creating many life-saving drugs, most of them have been developed by small biotech firms and start-ups that struggle to find clinical phase capacity."
"Recognising this gap and driven by our fundamental mission of creating access equity across the global healthcare ecosystem, Enzene Inc. has been launched in the US to establish a state-of-the-art manufacturing plant to cater to small and mid-sized biotech companies."
“We have successfully identified, leased, and set up our first manufacturing facility in the states in record time. We remain confident that our proprietary EnzeneX technology platform and proven track record in achieving cost-effective biologics manufacturing will see us emerge as a partner of choice for biotech companies as we support them in bringing promising molecules to market.”
Spread over 54,000 sqft, this plant will also hold the distinction of being one of the only biologics-focused continuous manufacturing bases to be set up by an Indian firm in the US.
The company narrowed down on New Jersey because of its long tradition of supporting pharmaceutical manufacturing excellence.
There is also ample availability of highly skilled talent in the region and Enzene Inc. is confident of securing skilled labor for sustained manufacturing operations over the longer term.
